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Abstract 
Background: Rheumatoid arthritis (RA) is a chronic inflammatory 
disease characterized by joint swelling and tenderness, with destruction of 
synovial joints, leading to severe disability and premature mortality. The 
etiology and pathogenesis of RA remain unknown, it is generally considered 
an autoimmune pathology in which autoreactive T cells of pathogenic 
potential, such as Th1 and Th17 cells, are thought to play an important role. 
Th17 cells selectively produce the signature cytokines such as IL-17, IL-21 
and IL-22, and have been demonstrated to play a critical role for the chronic 
inflammatory response and subsequent tissue damage in the affected joints. 
Objectives: To assess the role of IL-17A in RA; by estimation of the serum 
IL-17A levels in RA and apparently healthy controls, and assessing the 
association of serum IL-17A levels with disease activity and severity 
measured by DAS-28 by ESR. 
Patients and Methods: Cross-sectional analytic study carried out in the 
division of rheumatology/Shaheed Hemin general hospital, in Sulymaniyah 
city from (January 2015 to September 2015); on 45 RA patients; and 45 age 
and gender matched apparently healthy controls. Measurements of serum IL-
17A were done for both patients and controls by ELISA according to the 
manufacturer’s instructions. Disease activity was determined in the patients; 
according to DAS-28 by ESR. 
Results: A significant association was observed between serum IL-17A level 
and RA (p<0.001). There was a significant difference in serum IL-17A levels 
among RA patients on non-biological therapy and controls (p<0.001), also 
there was a significant difference in serum IL-17A levels among RA patients 
on biological therapy and controls (p<0.001), and no significant difference 
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was observed between the serum levels of IL-17A of RA patients on 
biological therapy and those on non-biological therapy (p=0.4), There was a 
significant association between serum IL-17A level and active RA disease 
(p<0.001). 
Conclusions: Serum IL-17A has a diagnostic value in RA, demonstrated by 
significant differences in serum IL-17A levels of RA patients and controls. 
Elevated serum IL-17A levels in RA patients parallel the degree of disease 
activity and severity. This may highlight the usefulness of IL-17A as a 
possible biomarker for more aggressive joint involvement and damage, 
giving it an important prognostic and predictive value. 
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Introduction 
 Rheumatoid arthritis (RA) is a chronic inflammatory disease 
characterized by joint swelling and tenderness, with destruction of synovial 
joints, leading to severe disability and premature mortality. Given the 
presence of autoantibodies, such as rheumatoid factor (RF) and anti–
citrullinated protein antibody (ACPA) (tested as anti–cyclic citrullinated 
peptide [anti-CCP]), which can precede the clinical manifestation of RA by 
many years (Aletaha D et al., 2010).The patient should fulfill the new 2010 
ACR/EULAR classification Criteria to be classified as definite RA, which is 
based on the confirmed presence of synovitis in at least 1 joint, absence of an 
alternative diagnosis that better explains the synovitis, and achievement of a 
total score of 6 or greater (of a possible 10) from the individual scores in 4 
domains: number and site of involved joints (score range 0–5), serologic 
abnormality (score range 0–3), elevated acute-phase response (score range 
0–1), and symptom duration (2 levels; range 0–1) (Aletaha D et al., 2010).  
 RA is considered an autoimmune disease marked by joint 
inflammation, T cell infiltration of the synovium, synovial hyperplasia, neo-
angiogenesis, involvement of many catabolic cytokines, and progressive 
destruction of articular cartilage and bone (Lubberts E et al., 2005). 
 The etiology and pathogenesis of RA remain unknown, it is generally 
considered an autoimmune pathology in which autoreactive T cells of 
pathogenic potential, such as Th1 and Th17 cells, are thought to play an 
important role (Park H et al., 2005) (Afzali B et al., 2007). 
 Cytokines play an important role in the pathogenesis of RA; they 
regulate a broad range of inflammatory processes that are implicated in the 
pathogenesis of RA. In rheumatoid joints, it is well known that an imbalance 
between pro- and anti-inflammatory activities favors the induction of 
autoimmunity, chronic inflammation, and joint damage; therefore, inhibiting 
the action of pro-inflammatory cytokines by using specific cytokine 
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inhibitors or anti-inflammatory cytokines is the basis for new therapies 
(McInnes IB and Schett G, 2007) (Richard OW et al., 2007). 
 Th17 cells selectively produce the signature cytokines such as IL-17, 
IL-21 and IL-22, and have been demonstrated to play a critical role for the 
chronic inflammatory response and subsequent tissue damage in RA affected 
joints (Hemdan NY et al., 2010). Moreover, IL-23 is a pro-inflammatory 
cytokine involved in differentiation and activation of Th17 cells to produce 
IL-17 which was found to play a critical role in other rheumatic diseases as 
inflammatory bowel disease (IBD) (Gheita TA et al., 20141) and Behçet's 
disease (Gheita TA et al., 20142). 
 IL-17A is the most studied family member of the IL-17 family 
consisting of six cytokines called IL-17A to IL-17F (Kolls JK and Linden A, 
2004). 
 The function of IL-17B-E is still poorly described, but IL-17A and 
IL-17F have been reported to have quite overlapping functions in 
autoimmunity, which could be explained by their structural homology. IL-
17A and IL-17F can be secreted as homodimer or heterodimer (IL-17A/F) 
and bind to the IL-17 receptor (IL-17R) complex that is widely expressed 
throughout the body (Wright JF et al., 2007). 
 In the early stages of RA pathogenesis, angiogenesis plays an 
important role. IL-17 potently contributes to this process, by stimulating 
fibroblast like synoviocytes (FLS) to produce vascular-endothelial growth 
factor (VEGF) (Ryu S et al., 2005). Concordantly, local over-expression of 
IL-17 increased the vascularity in mouse ankles; and in Matrigel plugs the 
cytokine promoted the growth of blood vessels (Pickens SR et al., 2010). 
Additionally, IL-17 induced the secretion of various inflammatory mediators 
like IL-6, IL-8, prostaglandin E2 (PGE2), and granulocyte colony 
stimulating factor (G-CSF) from synovial fibroblasts. Neutralizing IL-17 
(using a monoclonal antibody) blocked this induction, indicating that the 
effect is specific to thisTh17 cytokine (Fossiez F et al., 1996). As with 
synovial fibroblasts, IL-17 increased secretion of a select group of cytokines 
(e.g. IL-1b, TNFα, and IL-6) by human macrophages upon stimulation with 
recombinant protein (Jovanovic DV et al., 1998). In addition to the increased 
expression of these (pro-inflammatory) cytokines, IL-17 increased 
production of various matrix degrading enzymes, namely matrix 
metalloproteinase (MMP)-1, -2, -9, and -13 in whole synovial tissue, 
synovial fibroblasts, and cartilage (Moran EM et al., 2009). 
 Interestingly, various additive and synergistic effects were observed 
between IL-17 and the main cytokine known to be important in RA 
pathogenesis; TNF-α. For instance, combining IL-17 with TNF-α increased 
IL-6 secretion in an additive way, compared to secretion induced solely by 
IL-17. Furthermore, the combination of IL-17 and TNF-α induced GM-CSF 
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secretion by synovial fibroblasts, while the two cytokines separately showed 
no effect on GM-CSF secretion (Fossiez F et al., 1996). In murine knee 
joints, overexpression of solely IL-17 or TNF-α resulted in joint 
inflammation and bone erosion. Interestingly, when overexpressing both 
cytokines simultaneously, strikingly enhanced levels of joint inflammation 
and destructive capacity were observed. Additionally, S100A8, IL-1b, and 
MMP mRNA was strongly upregulated when both cytokines were 
overexpressed (Koenders MI et al., 2012). Treating mice during established 
arthritis with the combination of a soluble IL-17 receptor and TNF binding 
protein significantly inhibited further joint inflammation and cartilage 
destruction, more potently than either of the two anti-cytokine treatments 
alone (Koenders MI et al., 2011). 
 Neutralization of inflammatory mediators to reduce the progression 
of RA has been used successfully for several cytokines, particularly TNF-α. 
IL-17 is also an important mediator of RA pathology; as blockade of IL-17 in 
arthritis models reduces joint inflammation and bone erosion. Therefore, 
anti-IL-17 therapy is very interesting as an additional new anti-rheumatic 
strategy for RA (Sarah LG, 2004). 
 A recent study demonstrated that in RA patients not responding to 
treatment with the, overall very effective, biological targeting TNF-α, 
increased levels of both Th17 cells and cytokines were observed (Yue C et 
al., 2010). Since the group of anti-TNF non-responders accounts for 30% of 
the RA patients, it is important to 
 investigate other treatment options for those patients. As Th17 cells 
seem to be linked with anti-TNF non-responsiveness, those cells or its 
effector cytokines might be interesting new targets in RA therapy (Notley CA 
et al., 2008). 
Patients and Methods: A cross-sectional analytic study carried out 
in the division of rheumatology/Shaheed Hemin general hospital, in 
Sulymaniyah city from (January 2015 to September 2015), 45 rheumatoid 
arthritis patients were selected and fulfilled the 2010American College of 
Rheumatology (ACR) / European League against Rheumatism (EULAR) 
classification criteria for rheumatoid arthritis (Aletaha D et al., 2010) (Table 
1). 
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Table (1): 2010 ACR/EULAR Criteria for RA 
 
  
All patients were receiving disease modifying anti-rheumatic drugs 
(DMARDs), 23 patients on biological DMARDs, and 22 patients on non-
biological DMARDs. In addition, 45 apparently healthy controls (age and 
gender matched with the RA patients) were included in this study. 
 Informed consents were obtained from all subjects (patients and 
controls) and the study was approved by the local ethics committee. 
Full history taking and clinical examination were performed to the 
RA patients. Disease activity was assessed by measuring the disease activity 
score for 28 joints (DAS-28) by ESR (Prevoo ML et al., 1995) (Table 2). The 
DAS28 considers 28 tender and swollen joint counts, general health; patient 
assessment of disease activity using the 100 mm visual analog scale with 
0=best, 100=worst), plus levels of an acute phase reactant (ESR [mm/hour]). 
Table (2): DAS-28 Disease Activity Score for 28 joints 
DAS-28 Score Interpretation 
<2.6 Remission 
2.6-3.2 Low Disease Activity 
>3.2-5.1 Moderate Disease Activity 
>5.1 High Disease Activity 
 
Blood samples were withdrawn from all the patients and healthy 
controls.  Patients were subjected to the following laboratory Investigations: 
complete blood count (Advia60 cell counter; Bayer), erythrocyte 
sedimentation rate (ESR) mm/1st hour (Westergren method), serum C-
reactive protein (CRP), rheumatoid factor (RF), Measurement of IL-17A was 
done for both patients and healthy controls by ELISA according to the 
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manufacturer’s instructions (RayBiotech Human IL-17A ELISA Kit; USA). 
 
Statistical Analysis 
 All patients' data entered using computerized statistical software; 
Statistical Package for Social Sciences (SPSS) version 17 was used. 
Descriptive statistics presented as (mean ± standard deviation) and 
frequencies as percentages. Kolmogorov Smirnov analysis verified the 
normality of the data set. Multiple contingency tables conducted and 
appropriate statistical tests performed, t-test was used to compare between 
two means. One way ANOVA analysis was used to compare between more 
than two means. Pearson Correlation test was used to assess relationship 
between continuous variables. In all statistical analysis, level of significance 
(p value) set at ≤ 0.05 and the result presented as tables and/or graphs. 
 
Results 
 A total of 45 RA patients were included in this study with mean age 
of (49±14.4) years, females were more than males; with female to male ratio 
as 2.7:1 (Table 3). 
Table 3: Demographic Characteristics of RA Patients 
Variable  No. % 
Age  Mean±SD (49±14.4) Years 
20-29 years 5 11.1 
30-39 years 7 15.6 
40-49 years 9 20.0 
50-59 years 11 24.4 
≥ 60 years 13 28.9 
Total  45 100.0 
Gender  
Male  12 26.7 
Female  33 73.3 
Total  45 100.0 
 
Mean RA duration was 11.5±9.9 years, 62.2% of RA patients had RA 
duration as more than 5 years. Mean DAS-28 of RA patients was 5.03±1.4, 
22 RA patients had active RA disease, 17 RA patients had moderate disease, 
5 patients had low disease activity and only one patient had remission. (Table 
4) (Figure 1). 
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Table 4: Duration and DAS-28 of RA Patients 
Variable  No. % 
RA duration  Mean±SD (11.5±9.9) Years 
<=5 years 17 37.8 
> 5 years 28 62.2 
Total  45 100.0 
DAS-28   Mean±SD (5.03±1.4) 
Remission  1 2.2 
Low disease activity 5 11.1 
Moderate disease activity 17 37.8 
High disease activity  22 48.9 
Total  45 100.0 
 
Figure 1: DAS-28 of RA Patients 
 
 
 Mean ESR of RA patients was 44.3±20.5 mm/hr, 84.4% of RA 
patients had high ESR. CRP was positive among 66.7% of RA patients 
(Table 5). 
Table 5: ESR and CRP of RA Patients 
Variable  No. % 
ESR  Mean±SD (44.3±20.5 mm/hr) 
Normal  7 15.6 
High  38 84.4 
Total  45 100.0 
CRP 
Positive  30 66.7 
Negative  15 33.3 
Total  45 100.0 
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 More than half (51.1%) of RA patients were taking biologic therapy; 
and 48.9% of them were taking non-biologic therapy. Drugs taken by RA 
patients were distributed as the followings; Etanercept (35.6%), 
Methotrexate (35.6%), Rituximab (11.1%), HCQ (6.7%), Adalimumab 
(4.4%), SSZ (4.4%) and Leflonamide (2.2%). Most (91.1%) of RA patients 
had positive rheumatoid factor (RF) and 37.8% of them had positive family 
history (Table 6). 
Table 6: Mode of Therapy, RF and Family History of RA Patients 
Variable  No. % 
Therapy 
Biologic therapy 23 51.1 
Non-biologic therapy 22 48.9 
Total  45 100.0 
Drugs 
Etanercept 16 35.6 
Adalimumab 2 4.4 
Rituximab 5 11.1 
Leflonamide 1 2.2 
SSZ 2 4.4 
Methotrexate 16 35.6 
HCQ 3 6.7 
Total  45 100.0 
RF 
Positive  41 91.1 
Negative  4 8.9 
Total  45 100.0 
Family history  
Positive  17 37.8 
Negative  28 62.2 
Total  45 100.0 
 
 There was a significant association between IL-17A level and RA, as 
there were significant differences in the serum levels of IL-17A of RA 
patients and controls (p<0.001) (Table 7) (Figure 2). 
Table 7: IL-17A Mean Levels in RA Patients and Controls 
Variable   RA  Controls t-test P  
Mean±SD Mean±SD 
IL-17A 723.2±298.4 110.8±18 13.7 <0.001 
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Figure 2: IL-17A Mean Levels in RA Patients and Controls 
 
 
 There was a significant increase in IL-17A level in RA patients on 
non-biological therapy, compared to the controls (p<0.001). 
 There was a significant increase in IL-17A level in RA patients on 
biological therapy, compared to the controls (p<0.001). 
 No significant differences in IL-17A levels were observed between 
RA patients on biological therapy and those on non-biological therapy 
(p=0.6). (Table 8) (Table 9) (Figure 3) 
Table 8: IL-17A Levels in the Studied Groups 
Categories    IL-17A 
Mean±SD 
Cases on biological therapy  703.6±258.2 
Cases on non-biological therapy 743.7±340.3 
Controls 110.8±18 
ANOVA (P value) <0.001 
 
Table 9: IL-17A According to RA Therapy 
Variable   Biological   Non-Biological  t-test P  
Mean±SD Mean±SD 
IL17A 703.6±258.2 743.7±340.3 0.4 0.6 
 
 
 
 
 
 
 
110,8 
723,2 
0
100
200
300
400
500
600
700
800
Controls RA
M
ea
n 
European Scientific Journal November 2015 edition vol.11, No.33 ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
367 
Figure 3: IL-17A Levels in the Studied Groups 
 
 
 There was a significant association between IL-17A level and active 
RA disease (p<0.001) (Table 10).  
Table 10: Association between IL-17A and DAS-28 of RA Patients 
DAS-28    IL-17A  
Mean±SD 
Remission  295±0.0 
Low disease activity 459.6±87.7 
Moderate disease activity 638.4±152.3 
High disease activity 
  
868.2±338.1 
ANOVA (P value) <0.001 
 
 There was a significant association between IL-17A level and active 
RA disease in RA patients on biological therapy (p=0.03) (Table 11). 
Table 11: Association between IL-17A and DAS-28 of RA Patients on Biological Therapy 
DAS-28    IL-17A  
Mean±SD 
Low disease activity 322±0.0 
Moderate disease activity 576.3±132.7 
High disease activity 803.7±267.3 
ANOVA (P value) 0.03 
 
 A significant association was observed between IL-17A level and 
active RA disease among RA patients on non-biological therapy (p=0.03) 
(Table 12).  
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Table 12: Association between IL-17A and DAS-28 of RA Patients on non-Biological 
Therapy 
DAS-28    IL-17A  
Mean±SD 
Remission  295±0.0 
Low disease activity 494 ±48.8 
Moderate disease activity 693.6±153.9 
High disease activity 981.1±432.8 
ANOVA (P value) 0.03 
 
Discussion 
 Over the past few years, the importance of IL-17 and T helper 17 
(Th17) cells in the pathology of rheumatoid arthritis has become apparent. 
RA is a systemic autoimmune disease that affects up to 1% of the population 
worldwide. It is characterized by an inflamed, hyperplastic synovium with 
pannus formation, leading to bone and cartilage destruction in the joints. By 
the production of effector cytokines like IL-17 and IL-22, the T helper 17 
subset protects the host against bacterial and fungal infections, but it can also 
promote the development of various autoimmune diseases like RA. Hence, 
the Th17 pathway recently became a very interesting target in RA treatment. 
Up to now, several therapies targeting the Th17 cells or its effector cytokines 
have been tested, or are currently under investigation (Roeleveld DM, 
Koenders MI, 2015). 
 The current study demonstrated a significant association between 
serum IL-17A level and RA, as there were significantly higher serum IL-17A 
levels in the RA patients compared to the healthy controls. The results of 
several investigators were in agreement with these results, like (Metawi et 
al., 2011) reported significantly higher serum IL-17A levels in 30 RA 
patients than 13 healthy controls, and (Melis L et al., 2010) demonstrated a 
high serum IL-17 level in 22 RA patients. 
 Furthermore, (Mika K et al., 2008) showed that the level of IL-17 
gene expression in peripheral blood mononuclear cells (PBMC) from 52 RA 
patients was significantly higher than 34 controls (0.044±0.111 vs. 
0.013±0.003, respectively, p=0.011). While in another study Serum IL-17 
level was elevated in 41 RA patients compared to 21 healthy controls 
(Hitchon CA et al., 2004). 
 In addition, (Ziolkowska M et al., 2000) found a non-significantly 
higher serum IL-17 level in 15 RA patients compared to eight osteoarthritis 
(OA) patients (300 and 5 pg/mL, respectively). 
 To control the arthritis process by abrogation of inflammation, 
Disease Modifying Anti-Rheumatic Drugs (DMARDs) like methotrexate 
(MTX) and sulfasalazine are the first drugs to be administered to RA 
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patients. In the last decades, progress in the understanding of the cellular and 
molecular mechanisms of RA pathogenesis has led to the development of a 
new approach of treatment: the biologicals.  
 These biological agents can target a specific mediator of the disease, 
for example the pro-inflammatory cytokine TNF-α. Although the 
development and use of TNF-α inhibitors considerably improved prognosis 
of many RA patients, approximately 30% of patients still fail to respond 
adequately to this treatment. It was observed that in patients not responding 
to treatment with TNF-α inhibitors during RA therapy, circulating Th17 cell 
numbers were significantly higher compared to patients responding to 
treatment (Aerts NE et al., 2010) (Notley CA et al., 2008), suggesting that 
Th17 cells and Th17-derived cytokines might be interesting additional 
therapeutic targets in RA. 
 Very surprisingly, (Chen DY et al., 2011) reported that anti- TNF-α 
therapy causes a significant increase in Th17 cells in RA patients with an 
inadequate response to anti- TNF-α therapy. A high baseline level of IL-17 
may have a predictive value for poor therapeutic response to TNF-α 
inhibitors. These interesting findings highlight the crucial role of IL-17A in 
the pathogenesis of RA and urge the need for biological therapies targeting 
IL-17A pathway. 
 There was a significant association between serum IL-17A level and 
active RA disease, which is comparable to the results of (Al-Saadany HM et 
al., 2015), as they demonstrated significant correlations between Th-17 cell 
percentages and serum levels of IL-17, with disease activity (DAS-28), ESR, 
CRP, TNF-α and MRI score of synovitis, and scores for disease severity and 
joint destruction. 
 In another study, (Metawi  SA et al., 2011) revealed an increase in 
both serum and synovial IL-17A levels with higher DAS-28 scores and 
tender joint count (TJC), and increased serum IL-17A levels with higher 
swollen joint count (SJC). Similarly, (Melis L et al., 2010), reported elevated 
serum and synovial IL-17 levels in 22 RA patients that correlated 
significantly with local and systemic disease activity parameters. 
 
Conclusion 
 Serum IL-17A has a diagnostic value in RA, demonstrated by 
significant differences in serum IL-17A levels of RA patients and controls. 
 Elevated serum IL-17A levels in RA patients parallel the degree of 
disease activity and severity. This may highlight the usefulness of IL-17A as 
a possible biomarker for more aggressive joint involvement and damage, 
giving it an important prognostic and predictive value. 
 Knowing that IL-17A is a key cytokine that is implicated in driving 
disease activity in RA makes it a very interesting potential therapeutic target 
European Scientific Journal November 2015 edition vol.11, No.33 ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
370 
in RA treatment. Several therapies targeting IL-17A pathway have been 
tested, or are currently under investigation, with promising results as future 
novel biologic therapies in RA. 
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